Dysport Approval History

• FDA approved: Yes (First approved April 29th, 2009)
• Brand name: Dysport
• Generic name: abobotulinumtoxinA
• Dosage form: Injection
• Company: Ipsen Biopharmaceuticals, Inc.
• Treatment for: Cervical Dystonia, Facial Wrinkles, Upper Limb Spasticity

Dysport (abobotulinumtoxinA) is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the treatment of cervical dystonia, for the temporary improvement in the appearance of moderate to severe glabellar lines, for the treatment of spasticity in adults, and the treatment of lower limb spasticity in pediatric patients.

Development History and FDA Approval Process for Dysport

Date	Article
Jun 16, 2017	Ipsen Announces FDA approval of Dysport (abobotulinumtoxinA) for the Treatment of Lower Limb Spasticity in Adults
Aug  1, 2016	Ipsen Biopharmaceuticals, Inc. Announces FDA Approval of Dysport (abobotulinumtoxinA) for the Treatment of Lower Limb Spasticity in Pediatric Patients Aged Two and Older
Jul 17, 2015	Ipsen Announces FDA Approval of Dysport (abobotulinumtoxinA) for Upper Limb Spasticity
Apr 30, 2009	FDA Approves Dysport (abobotulinumtoxinA) for Cervical Dystonia and Glabellar Lines
Dec 29, 2008	FDA Issues Complete Response Letter to Ipsen for Dysport Biologics License Application
May 19, 2008	Ipsen and Medicis Announce Acceptance of Reloxin BLA in Aesthetics by FDA
Mar 17, 2008	Ipsen and Medicis Announce Submission of Reloxin BLA in Aesthetics to the FDA
Jan 31, 2008	Ipsen: FDA Accepts for Filing a Biologics License Application (BLA) for Dysport in Cervical Dystonia
Dec  6, 2007	Ipsen and Medicis Announce Submission of Reloxin in Aesthetics to the FDA
Dec  6, 2007	Ipsen Submits a Biologics License Application in Cervical Dystonia to the FDA for Dysport

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.